Study reveals recommended anti-clotting therapy for COVID patients

The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of anti-clotting treatment needed for patients hospitalised with COVID-19. Patients in hospital with COVID-19 are at increased risk of blood clots (or thromboses), which in turn may contribute to the development of organ failure. Almost all these patients will receive some degree of anti-clotting medication.

In an international study, the ASCOT team, including Prof Bala Venkatesh and Prof Vivek Jha from The George Institute, conducted a randomised clinical trial to test the different levels of anti-clotting medication in more than 1,500 patients in Australia, New Zealand, India and Nepal.

For details, refer to the media release on this page.

Leads

• Professor Vivekanand Jha

  Executive Director, The George Institute for Global Health, India

  

• Professor Bala Venkatesh

  Program Director, Critical Care